Genetics and molecular pathology of neuroendocrine gastrointestinal and pancreatic tumors (gastroenteropancreatic neuroendocrine tumors)

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 16, Issue 1, 2009, Pages 72-78

  Öberg, Kjell ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Carcinoid familial GI NETs; Gastrointestinal neuroendocrine tumors; Molecular genetics; Pancreatic endocrine tumors

Indexed keywords

BETA CATENIN; CALVASCULIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; INTERLEUKIN 6; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN P16; PROTEIN P53; SMAD3 PROTEIN; SMAD4 PROTEIN; TUBERIN; VON HIPPEL LINDAU PROTEIN;

CARCINOID; GASTROINTESTINAL TUMOR; GENE DELETION; GENE LOCATION; GENE LOCUS; GENE MUTATION; HISTOPATHOLOGY; HUMAN; MOLECULAR GENETICS; NEUROENDOCRINE TUMOR; PANCREAS TUMOR; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR CLASSIFICATION; WORLD HEALTH ORGANIZATION;

CARCINOID TUMOR; CARCINOMA, NEUROENDOCRINE; CHROMOSOME DELETION; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 18; GASTROINTESTINAL NEOPLASMS; GENE EXPRESSION PROFILING; HUMANS; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1; MUTATION; PANCREATIC NEOPLASMS;

EID: 58849090542     PISSN: 1752296X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MED.0b013e328320d845     Document Type: Review

References (69)

1. Calender A. Genetics of neuroendocrine tumours. In: Kvolls L, Caplin M, editors. Handbook of neuroendocrine tumours: their current and future management. Bristol: Bioscientifica; 2006. pp. 53-79.
2. Rindi G, Bordi C. Endocrine tumours of the gastrointestinal tract: aetiology, molecular pathogenesis and genetics. Best Pract Res Clin Gastroenterol 2005; 19:519-534.
3. Solcia E, Kloppel G, Sobin L. Histological typing of endocrine tumours. In: Verlag S, editor. World Health Organization histological classification of tumours, 2nd ed. Berlin, Heidelberg, New York, Geneva: Springer; 2000. pp. 38-74.
4. Rindi G, Kloppel G, Alhman H, et al. TNM staging of foregut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006; 449:395-401.
5. Rindi G, D'Adda T, Froio E, et al. Prognostic factors in gastrointestinal endocrine tumors. Endocr Pathol 2007; 18:145-149. This study is reviewing the previous WHO classification in neuroendocrine tumors and also discussing the proposal of tumor grading system (TNM classification) for patient's stratification. They suggest that this new classification system should be implemented in routine clinical practice. It is also now tested at different centers and seems to work quite well.
6. Akerstrom G, Hessman O, Hellman P, Skogseid B. Pancreatic tumours as part of the MEN-1 syndrome. Best Pract Res Clin Gastroenterol 2005; 19:819-830.
7. Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001; 86:5658-5671.
8. Marx SJ. Molecular genetics of multiple endocrine neoplasia types 1 and 2. Nat Rev Cancer 2005; 5:367-375.
9. Hessman O, Lindberg D, Einarsson A, et al. Genetic alterations on 3p, 11q13, and 18q in nonfamilial and MEN 1-associated pancreatic endocrine tumors. Genes Chromosomes Cancer 1999; 26:258-264.
10. Hessman O, Lindberg D, Skogseid B, et al. Mutation of the multiple endocrine neoplasia type 1 gene in nonfamilial, malignant tumors of the endocrine pancreas. Cancer Res 1998; 58:377-379.
11. Goebel SU, Heppner C, Burns AL, et al. Genotype/phenotype correlation of multiple endocrine neoplasia type 1 gene mutations in sporadic gastrinomas. J Clin Endocrinol Metab 2000; 85:116-123.
12. Gortz B, Roth J, Krahenmann A, et al. Mutations and allelic deletions of the MEN1 gene are associated with a subset of sporadic endocrine pancreatic and neuroendocrine tumors and not restricted to foregut neoplasms. Am J Pathol 1999; 154:429-436.
13. Shan L, Nakamura Y, Nakamura M, et al. Somatic mutations of multiple endocrine neoplasia type 1 gene in the sporadic endocrine tumors. Lab Invest 1998; 78:471-475.
14. Wang EH, Ebrahimi SA, Wu AY, et al. Mutation of the MENIN gene in sporadic pancreatic endocrine tumors. Cancer Res 1998; 58:4417-4420.
15. Wang DG, Johnston CF, Buchanan KD. Oncogene expression in gastroenteropancreatic neuroendocrine tumors: implications for pathogenesis. Cancer 1997; 80:668-675.
16. Iliopoulos O. von Hippel-Lindau disease: genetic and clinical observations. Front Horm Res 2001; 28:131-166.
17. Lott ST, Chandler DS, Curley SA, et al. High frequency loss of heterozygosity in von Hippel-Lindau (VHL)-associated and sporadic pancreatic islet cell tumors: evidence for a stepwise mechanism for malignant conversion in VHL tumorigenesis. Cancer Res 2002; 62:1952-1955.
18. Hammel PR, Vilgrain V, Terris B, et al. Pancreatic involvement in von Hippel-Lindau disease. The Groupe Francophone d'Etude de la Maladie de von Hippel-Lindau. Gastroenterology 2000; 119:1087-1095.
19. Blansfield JA, Choyke L, Morita SY, et al. Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs). Surgery 2007; 142:814-818; discussion 818 e811-e812. This is the greatest single center experience in patients with VHL disease and pancreatic endocrine tumors. Totally, 633 patients with VHL were evaluated in a prospective protocol between 1998 and 2006. Totally, 108 patients presented pancreatic neuroendocrine tumors (17%). Nine patients (8.3%) had metastatic disease from their pancreatic neuroendocrine tumors. Germline sequencing showed that 78% of patients with metastases had exon 3 mutations compared with 46% of patients without metastases.
20. Libutti SK, Choyke PL, Alexander HR, et al. Clinical and genetic analysis of patients with pancreatic neuroendocrine tumors associated with von Hippel-Lindau disease. Surgery 2000; 128:1022-1027; discussion 1027-1028.
21. Lubensky IA, Zhuang Z. Molecular genetic events in gastrointestinal and pancreatic neuroendocrine tumors. Endocr Pathol 2007; 18:156-162. This is an excellent review of molecular genetic events in gastrointestinal and pancreatic neuroendocrine tumors summarizing the most recent data.
22. Gutmann DH, Aylsworth A, Carey JC, et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 1997; 278:51-57.
23. Johannessen CM, Reczek EE, James MF, et al. The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci U S A 2005; 102:8573-8578.
24. Roach ES, Sparagana SP. Diagnosis of tuberous sclerosis complex. J Child Neurol 2004; 19:643-649.
25. Verhoef S, van Diemen-Steenvoorde R, Akkersdijk WL, et al. Malignant pancreatic tumour within the spectrum of tuberous sclerosis complex in childhood. Eur J Pediatr 1999; 158:284-287.
26. Eledrisi MS, Stuart CA, Alshanti M. Insulinoma in a patient with tuberous sclerosis: is there an association? Endocr Pract 2002; 8:109-112.
27. Speel EJ, Richter J, Moch H, et al. Genetic differences in endocrine pancreatic tumor subtypes detected by comparative genomic hybridization. Am J Pathol 1999; 155:1787-1794.
28. Stumpf E, Aalto Y, Hoog A, et al. Chromosomal alterations in human pancreatic endocrine tumors. Genes Chromosomes Cancer 2000; 29:83-87.
29. Speel EJ, Scheidweiler AF, Zhao J, et al. Genetic evidence for early divergence of small functioning and nonfunctioning endocrine pancreatic tumors: gain of 9Q34 is an early event in insulinomas. Cancer Res 2001; 61:5186-5192.
30. Zhao J, Moch H, Scheidweiler AF, et al. Genomic imbalances in the progression of endocrine pancreatic tumors. Genes Chromosomes Cancer 2001; 32:364-372.
31. Nagano Y, Kim do H, Zhang L, et al. Allelic alterations in pancreatic endocrine tumors identified by genome-wide single nucleotide polymorphism analysis. Endocr Relat Cancer 2007; 14:483-492. This study is reporting on genome-wide high-density SNP array analysis to detect copy number alteration using matched tumor and nonneoplastic tissue samples from 15 patients with pancreatic endocrine tumors. About 60% of pancreatic endocrine tumors had high allelic imbalances defined by more than four chromosomal aberrations and 40% of tumors had low allelic imbalances. The pancreatic endocrine tumors with high allelic imbalances were larger than tumors with lower imbalances. The study demonstrates chromosomal partial losses on chromosome 1, 3, 11 and 22 and gains of chromosome 5, 7, 12, 14, 17 and 20.
32. Muscarella P, Melvin WS, Fisher WE, et al. Genetic alterations in gastrinomas and nonfunctioning pancreatic neuroendocrine tumors: an analysis of p16/MTS1 tumor suppressor gene inactivation. Cancer Res 1998; 58:237-240.
33. Serrano J, Goebel SU, Peghini PL, et al. Alterations in the p16INK4a/CDKN2A tumor suppressor gene in gastrinomas. J Clin Endocrinol Metab 2000; 85:4146-4156.
34. Bartsch DK, Kersting M, Wild A, et al. Low frequency of p16 (INK4a) alterations in insulinomas. Digestion 2000; 62:171-177.
35. Chung DC, Smith AP, Louis DN, et al. Analysis of the retinoblastoma tumour suppressor gene in pancreatic endocrine tumours. Clin Endocrinol (Oxf) 1997; 47:523-528.
36. Wild A, Langer P, Ramaswamy A, et al. A novel insulinoma tumor suppressor gene locus on chromosome 22q with potential prognostic implications. J Clin Endocrinol Metab 2001; 86:5782-5787.
37. Chung DC, Brown SB, Graeme-Cook F, et al. Overexpression of cyclin D1 occurs frequently in human pancreatic endocrine tumors. J Clin Endocrinol Metab 2000; 85:4373-4378.
38. Chan AO, Kim SG, Bedeir A, et al. CpG island methylation in carcinoid and pancreatic endocrine tumors. Oncogene 2003; 22:924-934.
39. House MG, Herman JG, Guo MZ, et al. Aberrant hypermethylation of tumor suppressor genes in pancreatic endocrine neoplasms. Ann Surg 2003; 238:423-431; discussion 431-422.
40. Dammann R, Schagdarsurengin U, Strunnikova M, et al. Epigenetic inactivation of the Ras-association domain family 1 (RASSF1A) gene and its function in human carcinogenesis. Histol Histopathol 2003; 18:665-677.
41. Yashiro T, Fulton N, Hara H, et al. Comparison of mutations of ras oncogene in human pancreatic exocrine and endocrine tumors. Surgery 1993; 114:758-763; discussion 763-754.
42. Pavelic K, Hrascan R, Kapitanovic S, et al. Multiple genetic alterations in malignant metastatic insulinomas. J Pathol 1995; 177:395-400.
43. Lohmann DR, Funk A, Niedermeyer HP, et al. Identification of p53 gene mutations in gastrointestinal and pancreatic carcinoids by nonradioisotopic SSCA. Virchows Arch B Cell Pathol Incl Mol Pathol 1993; 64:293-296.
44. Pellegata NS, Sessa F, Renault B, et al. K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions. Cancer Res 1994; 54:1556-1560.
45. La Rosa S, Sessa F, Capella C, et al. Prognostic criteria in nonfunctioning pancreatic endocrine tumours. Virchows Arch 1996; 429:323-333.
46. Missiaglia E, Moore PS, Williamson J, et al. Sex chromosome anomalies in pancreatic endocrine tumors. Int J Cancer 2002; 98:532-538.
47. Beghelli S, Pelosi G, Zamboni G, et al. Pancreatic endocrine tumours: evidence for a tumour suppressor pathogenesis and for a tumour suppressor gene on chromosome 17p. J Pathol 1998; 186:41-50.
48. Rigaud G, Missiaglia E, Moore PS, et al. High resolution allelotype of nonfunctional pancreatic endocrine tumors: identification of two molecular subgroups with clinical implications. Cancer Res 2001; 61:285-292.
49. Duerr EM, Mizukami Y, Ng A, et al. Defining molecular classifications and targets in gastroenteropancreatic neuroendocrine tumors through DNA microarray analysis. Endocr Relat Cancer 2008; 15:243-256. This recent study has identified a novel set of genes that may play a role in the pathogenesis and progression of pancreatic neuroendocrine tumors. The authors could clearly separate a benign gene cluster from a malignant gene cluster that correlated with WHO histological classification. The paper gives new insight into the molecular biology and tumor pathogenesis.
50. D'Adda T, Keller G, Bordi C, Hofler H. Loss of heterozygosity in 11q13-14 regions in gastric neuroendocrine tumors not associated with multiple endocrine neoplasia type 1 syndrome. Lab Invest 1999; 79:671-677.
51. Debelenko LV, Emmert-Buck MR, Zhuang Z, et al. The multiple endocrine neoplasia type I gene locus is involved in the pathogenesis of type II gastric carcinoids. Gastroenterology 1997; 113:773-781.
52. D'Adda T, Pizzi S, Azzoni C, et al. Different patterns of 11q allelic losses in digestive endocrine tumors. Hum Pathol 2002; 33:322-329.
53. Pizzi S, Azzoni C, Bassi D, et al. Genetic alterations in poorly differentiated endocrine carcinomas of the gastrointestinal tract. Cancer 2003; 98:1273-1282.
54. Rindi G, Villanacci V, Ubiali A, Scarpa A. Endocrine tumors of the digestive tract and pancreas: histogenesis, diagnosis and molecular basis. Expert Rev Mol Diagn 2001; 1:323-333.
55. D'Adda T, Candidus S, Denk H, et al. Gastric neuroendocrine neoplasms: tumour clonality and malignancy-associated large X-chromosomal deletions. J Pathol 1999; 189:394-401.
56. Lollgen RM, Hessman O, Szabo E, et al. Chromosome 18 deletions are common events in classical midgut carcinoid tumors. Int J Cancer 2001; 92:812-815.
57. Terris B, Meddeb M, Marchio A, et al. Comparative genomic hybridization analysis of sporadic neuroendocrine tumors of the digestive system. Genes Chromosomes Cancer 1998; 22:50-56.
58. Zhao J, de Krijger RR, Meier D, et al. Genomic alterations in well differentiated gastrointestinal and bronchial neuroendocrine tumors (carcinoids): marked differences indicating diversity in molecular pathogenesis. Am J Pathol 2000; 157:1431-1438.
59. Kytola S, Hoog A, Nord B, et al. Comparative genomic hybridization identifies loss of 18q22-qter as an early and specific event in tumorigenesis of midgut carcinoids. Am J Pathol 2001; 158:1803-1808.
60. Arnold CN, Sosnowski A, Schmitt-Graff A, et al. Analysis of molecular pathways in sporadic neuroendocrine tumors of the gastro-entero- pancreatic system. Int J Cancer 2007; 120:2157-2164. This study is presenting genetic alterations as well as the CpG island methylation phenotype (CIMP). Significant differences in promoter hypermethylation were identified in the RUNX3 and the O6-MGMT gene. They could also demonstrate correlation between CIMP and the Ki-67 index above 10% indicating a prognostic relevance for both of them.
61. Tannapfel A, Vomschloss S, Karhoff D, et al. BRAF gene mutations are rare events in gastroenteropancreatic neuroendocrine tumors. Am J Clin Pathol 2005; 123:256-260.
62. Ramnani DM, Wistuba II, Behrens C, et al. K-ras and p53 mutations in the pathogenesis of classical and goblet cell carcinoids of the appendix. Cancer 1899; 86:14-21.
63. Fujimori M, Ikeda S, Shimizu Y, et al. Accumulation of beta-catenin protein and mutations in exon 3 of beta-catenin gene in gastrointestinal carcinoid tumor. Cancer Res 2001; 61:6656-6659.
64. Su MC, Wang CC, Chen CC, et al. Nuclear translocation of beta-catenin protein but absence of beta-catenin and APC mutation in gastrointestinal carcinoid tumor. Ann Surg Oncol 2006; 13:1604-1609.
65. Fujiki K, Duerr EM, Kikuchi H, et al. Hoxc6 is overexpressed in gastrointestinal carcinoids and interacts with JunD to regulate tumor growth. Gastroenterology 2008; 135:907-916; discussion 916 e901-e902. The homeobox gene Hoxc6 was highly upregulated in human gastrointestinal carcinoid tumors. By establishing carcinoid cells that stably overexpressed Hoxc6 or were deficient of Hoxc6 cellular proliferation assay, luciferase reporter assays, western blotting, immunoprecipitation, DNA affinity precipitation and DNA microarray could demonstrate that Hoxc6 overexpression stimulates the cell proliferation and knockdown inhibited their growth. Hoxc6 activated the oncogenic activator protein-1 signaling pathway through a physical interaction with JunD. Hoxc6 also induced the expression of genes that characteristically are upregulated in carcinoid tumors including neurotensin and connected tissue growth factors.
66. Kidd M, Modlin IM, Mane SM, et al. The role of genetic markers - NAP1L1, MAGE-D2, and MTA1 - in defining small-intestinal carcinoid neoplasia. Ann Surg Oncol 2006; 13:253-262.
67. Berkovic MC, Jokic M, Marout J, et al. IL-6-174 C/G polymorphism in the gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Exp Mol Pathol 2007; 83:474-479. This study is reporting on IL-6 in 80 patients with GEP-NETs. IL-6 is a pleiotropic cytokine with a still controversial role in tumorigenesis of different cancer types. This study is reporting about higher serum IL-6 values in GEP-NETs patients compared with healthy controls (36.8%). Phenotype analysis showed that the majority of the patients had genotype GG IL-6-174. This correlation between serum IL-6 values and the IL-6-174 genotype was particularly significant in nonfunctioning GEP-NETs.
68. Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008; 9:61-72. This study is reviewing the current status of tumor biology and clinical management of gastroenteropancreatic neuroendocrine tumors. This study is summarizing the requirements for an improvement in neuroendocrine tumors outcome with refinement of the universal classification and grading system. The study further elucidates the cell biology, development of cell lines and animal models, acquisition of genetic information and identification of serum marker for early diagnosis. Furthermore, definition of tissue markers to identify tumor origin and the molecular pathology profiling to define prognosis are needed in the future.
69. Perren A, Anlauf M, Komminoth P. Molecular profiles of gastroenteropancreatic endocrine tumors. Virchows Arch 2007; 451 (Suppl 1):S39-S46. This study is summarizing the current knowledge in the molecular profiles of GEP-NET tumors.